Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Financing Activities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Cash from Financing Activities for 11 consecutive years, with -$52000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 106.64% to -$52000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.1 million, a 104.78% decrease, with the full-year FY2025 number at -$8.1 million, down 104.78% from a year prior.
  • Cash from Financing Activities was -$52000.0 for Q4 2025 at Cartesian Therapeutics, down from -$38000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $124.5 million in Q3 2024 to a low of -$24.8 million in Q3 2023.
  • A 5-year average of $12.6 million and a median of $783000.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 4150.49% in 2023, then soared 28779.87% in 2024.
  • Cartesian Therapeutics' Cash from Financing Activities stood at $21.2 million in 2021, then crashed by 97.11% to $612000.0 in 2022, then surged by 2200.82% to $14.1 million in 2023, then crashed by 94.44% to $783000.0 in 2024, then plummeted by 106.64% to -$52000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Cash from Financing Activities are -$52000.0 (Q4 2025), -$38000.0 (Q3 2025), and $60000.0 (Q2 2025).